Unspecified Antineoplastic Agent


Combined with:

Neulasta

Indications and Reactions:

Role Indications Reactions
Secondary
Chemotherapy 44.0%
Gastrointestinal Stromal Tumour 24.0%
Anaemia Of Malignant Disease 12.0%
Drug Use For Unknown Indication 8.0%
Idiopathic Thrombocytopenic Purpura 8.0%
Pancreatic Carcinoma 4.0%
White Blood Cell Count Increased 26.7%
Musculoskeletal Stiffness 13.3%
Vomiting 13.3%
Alveolitis Allergic 6.7%
Dehydration 6.7%
Herpes Simplex 6.7%
Neutropenic Sepsis 6.7%
Thrombocytopenia 6.7%
Thrombosis 6.7%
Transient Ischaemic Attack 6.7%
Concomitant
Chemotherapy 65.1%
Anaemia Of Malignant Disease 13.6%
Idiopathic Thrombocytopenic Purpura 5.1%
Neutropenia 4.7%
Drug Use For Unknown Indication 2.7%
Rheumatoid Arthritis 1.6%
Non-hodgkin's Lymphoma 1.1%
Ovarian Cancer 0.9%
Anaemia 0.7%
Colorectal Cancer 0.7%
Product Used For Unknown Indication 0.7%
Psoriatic Arthropathy 0.7%
Squamous Cell Carcinoma 0.7%
Myelodysplastic Syndrome 0.4%
Osteoporosis Postmenopausal 0.4%
Acute Myeloid Leukaemia 0.2%
Mucosal Inflammation 0.2%
Neoplasm Malignant 0.2%
Psoriasis 0.2%
Renal Failure Chronic 0.2%
Febrile Neutropenia 11.5%
White Blood Cell Count Decreased 10.5%
Neutropenia 9.1%
Death 7.7%
Thrombocytopenia 7.2%
Therapeutic Response Decreased 5.3%
Rash 4.8%
Sepsis 4.8%
Malaise 4.3%
Pain 3.8%
Vomiting 3.8%
White Blood Cell Count Increased 3.8%
Drug Ineffective 3.3%
Myalgia 3.3%
Overdose 3.3%
Back Pain 2.9%
Dyspnoea 2.9%
Pyrexia 2.9%
Carbohydrate Antigen 15-3 Increased 2.4%
Pain In Extremity 2.4%

Drug Data